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INTRODUCTION
Heterogeneously vancomycin-resistant Staphylococcus aureus
(hetero-VRSA) may account for treatment failure with van-
comycin in methicillin-resistant S. aureus (MRSA) infections
and act as a precursor of S. aureus that are fully or intermedi-
ately resistant to vancomycin (1). Since it was introduced as
a different type of vancomycin resistance, there have been many
tests to isolate hetero-VRSA from clinical MRSA strains and
to evaluate their clinical relevance. The detection rates varied
depending on the researchers, which might have resulted from
a confusing definition and unreliable screening methods of
hetero-VRSA (1-3). Hetero-VRSA was defined by Aritaka et
al.: as an S. aureus strain whose vancomycin minimum inhibito-
ry concentration (MIC) is less than 8  g/mL determined by the
NCCLS-based broth dilution method, which contains subpop-
ulations of cells that are resistant to higher concentrations of
vancomycin (including 4  g/mL of vancomycin), and whose
mutant strains with increased vancomycin resistance (a MIC
of  8  g/mL) can be obtained by the one-step vancomycin-
selection procedure with a frequency of 1 in 106or greater (4).
While investigators continue to search for effective com-
bination therapies against infection caused by S. aureus strains
with reduced susceptibilities to vancomycin, there have been
contradictory results on the interaction between vancomycin
and  -lactam antibiotics. Vancomycin and  -lactams showed
antagonistic interactions against Mu 3, whereas other reports
documented synergistic interactions between these antibi-
otics against other S. aureus strains with reduced susceptibil-
ities to vacomycin (4-8). In order to evaluate the efficacy of
vancomycin- -lactam combinations against hetero-VRSA
strains, we performed population analyses of Mu 3 and other
hetero-VRSA strains in a wide range of antibiotic concen-
trations.
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There have been conflicting data about the interactions between vancomycin
and  -lactam agents against Staphylococcus aureus strains with heteroge-
neous resistance to vancomycin. We evaluated the efficacy of these combina-
tions against Mu 3 and heterogeneously vancomycin-resistant S. aureus (het-
ero-VRSA) strains which were isolated from Korean patients using a population
analysis method. Antagonistic effects were observed when less than 1  g/mL of
-lactam antibiotics was combined with vancomycin, whereas synergistic effects
were noticed with more than 4  g/mL of  -lactam antibiotics. The antagonistic
effects at low concentrations of  -lactams were most prominent at 2  g/mL of
vancomycin, which were the vancomycin MICs of tested hetero-VRSA strains.
This study showed the variable effects of vancomycin- -lactam combinations
depending on the concentrations of  -lactam antibiotics and this property could
be used to develop screening methods for hetero-VRSA strains.
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MATERIALS AND METHODS 
Bacterial strains and antibiotics
Mu 3 and two other hetero-VRSA strains (Sm 1272 and
Sm 1299) were used in this study. Sm 1272 and Sm 1299
were isolated from two patients who had been treated with
vancomycin for MRSA infections at Samsung Medical Cen-
ter, Seoul, Korea. Tested strains were cultured overnight on
tryptic soy agar (BD, Cockeysville, MD, U.S.A.) with 5%
sheep blood at 37 with aeration. Oxacillin, cefotaxime,
and vancomycin were used (Sigma Chemical Co., St. Louis,
MO, U.S.A.).
Susceptibility tests to vancomycin
The MIC of vancomycin was determined by both broth
dilution and population analysis methods. Mueller-Hinton
broth (Difco Laboratories, Detroit, MI, U.S.A.) and brain-
heart infusion (BHI) agar (BD, Cockeysville, MD, U.S.A.)
were used for broth dilution and population analyses, respec-
tively. Broth dilution was performed according to the NCCLS
guidelines (9). In population analysis methods, vancomycin
was increased by 2  g/mL increments from 2 to 10  g/mL.
Population analyses were done by spreading 50  L of starting
cell suspension (108 cfu/mL) cultured overnight and its dilu-
ents on BHI agar plates containing various concentrations of
vancomycin. These plates were incubated at 37 for 48 hr. 
Population analyses for the efficacy of vancomycin- -
lactam combinations
In order to evaluate the interaction between vancomycin
and  -lactam antibiotics, population analyses with BHI agar
were performed. The  -lactam antibiotics used in the study
were oxacillin and cefotaxime. Vancomycin was increased
by 2  g/mL increments in the range of 0-8  g/mL and the
concentrations of  -lactam antibiotics combined with van-
comycin were 0.06, 0.125, 0.5, 4, or 8  g/mL. Each bacte-
rial strain was cultured overnight and then plated at several
dilutions on BHI agar plates containing various concentra-
tions of vancomycin and  -lactam antibiotics. Conditions
for population analysis were the same as those for the deter-
mination of MIC. All the tests were repeated over five times.
RESULTS
Vancomycin MICs of Mu 3, Sm 1272, and Sm 1299 were
all 2  g/mL by the broth dilution and population analysis
methods. Oxacillin MICs of Sm 1272 and Sm 1299 were
more than 128  g/mL by disc diffusion methods. Popula-
tion analysis profiles of Sm 1272 and Sm 1299 were similar
to those of Mu 3 (Fig. 1). Although vancomycin MICs of
the tested strains were 2  g/mL, some subpopulations of
Sm 1272 and Sm 1299 grew on the agar plates containing
4 to 8  g/mL of vancomycin, and mutant strains with van-
comycin MIC of  8  g/mL were also obtained from these
strains by one-step vancomycin-passage with a frequency of
10-6. These two strains could be designated as hetero-
VRSA according to definition of Aritaka et al. (4).
The results of population analyses of Mu 3, Sm 1272, and
Sm 1299 against combinations of vancomycin and oxacillin
are shown in Fig. 2. The number of surviving colonies in-
creased when 0.06, 0.125, or 0.5  g/mL of oxacillin was
combined with vancomycin. When 4 or 8  g/mL of oxacillin
was combined with vancomycin, the number of surviving
colonies decreased for all of the three hetero-VRSA strains.
Fig. 3 shows the population analysis profiles of these strains
against vancomycin and another  -lactam agent, cefotaxime.
Similarly, more colonies survived when less than 1  g/mL of
cefotaxime was combined with vancomycin, while fewer
colonies survived at 4 or more  g/mL of cefotaxime com-
bined with vancomycin. The antagonistic effects were most
prominent when oxacillin or cefotaxime was combined with
2  g/mL of vancomycin, which were vancomycin MICs of
tested hetero-VRSA strains.
DISCUSSION 
S. aureus continues to be one of the most common causes
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Fig. 1. Susceptibility tests to vancomycin by population analyses.
Mu 3, Sm 1272, and Sm 1299 have similar population analysis
profiles against vancomycin. The MICs of vancomycin, as deter-
mined from the population analysis profiles, are 2  g/mL for Mu
3, Sm 1272, and Sm 1299. Sm 1272 grows on the agar plates
containing 4  g/mL of vancomycin at a frequency of more than
10
-6 colonies, and some subpopulations of Sm 1299 and Mu 3
grow on the agar plates containing 8  g/mL of vancomycin.Vancomycin- -lactam Combinations Against Hetero-VRSA 321
of nosocomial and community-acquired infections in the
world. The spread of MRSA in hospitals and in the com-
munity resulted in widespread vancomycin use in S. aureus
infections (10, 11). With the widespread use of vancomycin,
the first clinical isolate of S. aureus with intermediate resis-
tance to vancomycin (VISA) was reported from Japan in 1996
and multiple strains of S. aureus with reduced susceptibili-
ties to vancomycin have been reported in other countries
(12-17). The emergence of reduced vancomycin susceptibil-
ity in S. aureus made many clinicians concerned about the
possibility that some strains would become fully resistant,
and actually vancomycin-resistant S. aureus (VRSA) strains
have been isolated from Michigan and Pennsylvania in 2002
(18, 19).
The advance of VRSA has added a grave concern to the
therapeutic dilemma caused by the presence of multidrug-
resistant organisms in recent years. Therapeutic failures with
vancomycin, however, have already been reported for infec-
tions caused by MRSA strains (20). It was suggested that
the presence of hetero-VRSA strains among MRSA strains
might be responsible for vancomycin failure against MRSA
infections, and that VRSA strains might have originated
from pre-existing MRSA strains after prolonged exposure to
vancomycin through hetero-VRSA (4). This possibility indi-
cated a need to survey for the presence of hetero-VRSA strains
among MRSA isolates and to evaluate their clinical relevance.
The original screening methods suggested by Hiramatsu et al.
(1), however, were found to have poor reproducibility and may
select vancomycin resistance (21). This may partly explain the
variable detection rates (0-47%) of hetero-VRSA strains and
Fig. 2. Population analyses of hetero-VRSA strains against van-
comycin-oxacillin combinations. The number of surviving colo-
nies increase when 0.06 (dotted line with open triangles), 0.125
g/mL (dotted line with solid circles), or 0.5  g/mL (dotted line
with open circles) of oxacillin was combined with vancomycin.
These increments are most prominent at 2  g/mL of vanco-
mycin. Fewer colonies survive when 4 (thin solid line with open
diamonds) or 8  g/mL (thin solid line with solid diamonds) of oxa-
cillin was combined (thick solid line with solid squares denotes
vancomycin alone).
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the conflicting data about their clinical significance (1-3, 16).
Some researchers reported vancomycin failure for treatment of
hetero-VRSA infections, while others presented most of het-
ero-VRSA infections had been controlled successfully with
vancomycin alone (2, 16). The exact clinical significance of
hetero-VRSA infection awaits a well-designed prospective
case-controlled study.
For the purpose of discovering effective therapeutic regi-
mens for infections caused by S. aureus strains with reduced
susceptibility to vancomycin, combination methods of cur-
rent antibiotics have been tested in many laboratories. Hana-
ki et al. documented antagonistic interactions between van-
comycin and ceftizoxime against Mu 3, and he developed
Mu 3 agar on the basis of these findings for the detection of
hetero-VRSA (6). Besides these, many other results have been
reported regarding the efficacy of vancomycin- -lactam
combinations against S. aureus strains with reduced suscep-
tibilities to vancomycin-synergistic (or additive) and antag-
onistic effects (7, 8, 22-26). 
This study showed antagonistic effects against hetero-VRSA
strains when low concentrations (<1.0  g/mL) of oxacillin
or cefotaxime were combined with vancomycin, while syn-
ergistic effects were attained when high concentrations (>4.0
g/mL) of  -lactams were combined (oxacillin MICs of het-
ero-VRSA strains tested in this study were more than 128
g/mL). Haraga et al. also performed population analyses with
several hetero-VRSA strains to evaluate combination effects
(22). Their data demonstrated similar results to ours, that is
antagonistic effects at <1  g/mL but synergistic effects at
>8  g/mL of  -lactam antibiotics (in their data, they did
Fig. 3. Population analyses of hetero-VRSA strains against van-
comycin-cefotaxime combinations. The number of surviving colo-
nies increase when 0.06 (dotted line with open triangles), 0.125
(dotted line with solid circles), or 0.5 (dotted line with open circles)
g/mL of cefotaxime was combined with vancomycin, while the
number decreases when 4 (thin solid line with open diamonds) or
8 (thin solid line with solid diamonds)  g/mL of cefotaxime was
combined (thick solid line with solid squares denotes vancomycin
alone).
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not evaluate combination effects with 4  g/mL of  -lactams).
Aritaka et al. (4) and Howe et al. (23) each presented that  -
lactams showed antagonism at concentrations below their
MICs but synergy at concentrations near the MICs, against
hetero-VRSA strains, when combined with vancomycin. In
data presented by Hiramatsu et al. the concentrations of  -
lactams showing antagonism against Mu 3 were 0.125-4  g/
mL for ampicillin and 0.03-4  g/mL for oxacillin, while those
demonstrating synergy were 8-16  g/mL for ampicillin (MIC,
32  g/mL) and 512  g/mL for oxacillin (MIC, 1,024  g/mL).
Most of data consistently presented antagonism when low
concentrations (<1.0  g/mL) of  -lactams were combined
with vancomycin, regardless of the testing methods. On the
contrary, there was great discrepancy between the concentra-
tions of  - lactams showing synergy of the individual data-
from 4 or 8  g/mL of oxacillin in our data to 512  g/mL of
the same antibiotic In data presented by Hiramatsu et al. This
discrepancy may come from the difference of testing methods.
Instead of population analyses used by our and Haragas study,
Hiramatsu et al. adopted the broth dilution methods and
Howe used the E-test to evaluate the combination effects (4,
22, 23). There are also other reports regarding the combina-
tion effects of vancomycin- -lactams (7, 8, 24-26). It seems
difficult, however, to compare those data with ours directly
since the testing methods and tested strains were different from
ours. The proper methods for evaluating vancomycin- -lac-
tam combination effects against hetero-VRSA strains as well
as the more reliable screening methods for hetero-VRSA should
be developed.
Although the mechanism of antagonism or synergy depend-
ing on the concentrations of  -lactams is unknown, it is
suggested that the existence of low concentrations of  -lac-
tam antibiotics may induce activation of cell wall synthesis
or reduce the cross-linking of peptidoglycan of hetero-VRSA
strains. Reduced cross-linking increases the number of D-
alanyl-D-alanine residues in the cell wall, which trap more
vancomycin molecules within the cell wall layers, thereby
preventing the access of vancomycin molecules to their tar-
get on the cytoplasmic membrane (4). Inversely, high con-
centrations of  -lactam antibiotics may cause inhibition of
synthesis of proteins essential for the expression of vancomycin
resistance, producing synergy (23).
The concentrations of oxacillin showing synergy in this
study (4 or 8  g/mL) are clinically achievable, but those in
data presented by Hiramatsu et al. (512  g/mL) are not (4).
With all data accumulated so far, it is difficult to conclude that
vancomycin- -lactam combinations are synergistic or antag-
onistic against hetero-VRSA strains at clinically achievable
concentrations of  -lactams. The more in vitro and in vivo
studies are required to elucidate the real efficacy of vancomy-
cin- -lactam combinations at clinically achievable concen-
trations against hetero-VRSA strains. Interestingly, synergis-
tic or antagonistic effects of vancomycin- -lactam combina-
tions depending on the concentrations of  -lactams seem to
be unique for hetero-VRSA strains, not observed against most
of MRSA or VISA strains. This property can be used to devel-
op the more reliable methods to screen hetero-VRSA from
MRSA strains. 
Despite continuing debates about the efficacy of vanco-
mycin- -lactam combinations, this study presents evidence
reminding that we must be prudent in choosing such a com-
bination for treating infections caused by S. aureus with pos-
sibly reduced susceptibilities to vancomycin in patients who
have a history of prolonged exposure to vancomycin.
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